A Phase 1 First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of ABBV-623 and ABBV-992 in Subjects With B-cell Malignancies
Latest Information Update: 07 Feb 2023
At a glance
- Drugs ABBV-623 (Primary) ; ABBV-992 (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors AbbVie
- 02 Feb 2023 Status changed from active, no longer recruiting to discontinued.
- 09 Dec 2022 Planned End Date changed from 31 Jan 2023 to 1 May 2023.
- 09 Dec 2022 Planned primary completion date changed from 31 Jan 2023 to 1 May 2023.